Daniel Walden
Overview
Explore the profile of Daniel Walden including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
10
Citations
23
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Eslinger C, Walden D, McGary A, Emiloju O, Ahn D, Sonbol M, et al.
Cancer
. 2025 Feb;
131(4):e35756.
PMID: 39932790
Background: Alterations in mismatch repair (MMR) genes like MLH1, MSH2, MSH6, and PMS2 can lead to microsatellite instability-high (MSI-H) tumors. These mutations can be inherited, as in Lynch syndrome (LS),...
2.
Desai A, Xiao A, Choi D, Toruner M, Walden D, Halfdanarson T, et al.
Cancers (Basel)
. 2024 May;
16(10).
PMID: 38791940
Purpose: To investigate the molecular characteristics of and potential for precision medicine in KRAS wildtype pancreatic ductal adenocarcinoma (PDAC). Patients And Methods: We investigated 27 patients with PDAC at our...
3.
Eslinger C, Walden D, Barry T, Shah S, Samadder N, Bekaii-Saab T
J Natl Compr Canc Netw
. 2023 Sep;
21(9):894-899.
PMID: 37673116
Immune checkpoint inhibitors (ICIs) induce profound benefits in cancer patients with mismatch repair gene mutations or high levels of microsatellite instability. Herein, we present a case of a patient with...
4.
Marwah H, Hampshire K, Sood N, Fritz D, Brewer T, Walden D, et al.
EBioMedicine
. 2023 Jul;
93:104693.
PMID: 37407347
No abstract available.
5.
6.
Walden D, Eslinger C, Bekaii-Saab T
Therap Adv Gastroenterol
. 2022 Aug;
15:17562848221115317.
PMID: 35967919
Biliary tract cancers are a diverse and aggressive malignancy that carry a poor chance for curative treatment and significant associated mortality. Current first-line treatment only extends median overall survival to...
7.
Walden D, Rawls M, Santen S, Feldman M, Vinnikova A, Dow A
Med Sci Educ
. 2022 Jun;
32(4):819-826.
PMID: 35729989
Introduction: Medical schools vary in their approach to providing feedback to faculty. The purpose of this study was to test the effects of rapid student feedback in a course utilizing...
8.
Ahn D, Walden D, Bekaii-Saab T
Expert Opin Investig Drugs
. 2022 Mar;
31(5):437-441.
PMID: 35289234
Introduction: Human epidermal growth factor receptor 2 (HER-2) is an oncogenic driver and target in gastroesophageal and breast cancer; there is also evidence for a role in non-small cell lung...
9.
Walden D, Sonbol M, Petty S, Yoon H, Borad M, Bekaii-Saab T, et al.
Front Oncol
. 2021 Sep;
11:641044.
PMID: 34568002
Background: Fluoropyrimidine with platinum-based chemotherapy has become the standard of care for advanced gastric and gastroesophageal (GEJ) cancer. Trials in colon cancer show that induction chemotherapy followed by maintenance chemotherapy...
10.
Walden D, Kunnimalaiyaan S, Sokolowski K, Clark T, Kunnimalaiyaan M
Oncotarget
. 2017 Nov;
8(50):88069-88078.
PMID: 29152142
Cholangiocarcinoma remains the second most prevalent hepatic neoplasm in the United States with a 5-year survival rate of less than 10%. Currently, no systemic therapy has demonstrated efficacy. Therefore, an...